Psychotropic medication for behaviour problems in people with intellectual disability: A review of the current literature

Current Opinion in Psychiatry

Volumn 20, Issue 5, 2007, Pages 461-466

  Deb, Shoumitro ^a   Unwin, Gemma L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Behaviour problems; Intellectual disability; Medication

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOMIPRAMINE; CLOZAPINE; ESTROGEN; FLUOXETINE; FLUVOXAMINE; METHYLPHENIDATE; MOOD STABILIZER; NALTREXONE; OLANZAPINE; OPIATE ANTAGONIST; PAROXETINE; PLACEBO; PROGESTERONE; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROIC ACID; ZINC;

ABDOMINAL PAIN; AGGRESSION; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESEARCH; DRUG WITHDRAWAL; HEADACHE; HUMAN; INSOMNIA; INTELLECTUAL IMPAIRMENT; LOW DRUG DOSE; METHODOLOGY; RESTLESSNESS; REVIEW; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

HUMANS; MENTAL DISORDERS; MENTAL RETARDATION; PSYCHOTROPIC DRUGS;

EID: 34548416670     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3282ab9952     Document Type: Review

References (41)

1. Holden B, Gitlesen JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil 2004; 25:509-521.
2. Deb S, Thomas M, Bright C. Mental disorder in adults with intellectual disability. 1: Prevalence of functional psychiatric illness among a community-based population aged between 16-64 years. J Intellect Disabil Res 2001; 45:495-505.
3. Deb S, Clarke D, Unwin G. Using medication to manage behaviour problems among adults with a learning disability: Quick Reference Guide (QRG). University of Birmingham, Royal College of Psychiatrists, Mencap; 2007. A recently published guideline that provides recommendations of good clinical practice surrounding the use of psychotropic medication to manage behaviour problems. It followed the guideline development methods stipulated by the National Institute for Health and Clinical Excellence and provides an overview of what is considered as best practice in the field. Available www.LD-Medication.bham.ac.uk
4. Deb S, Unwin GL, Soni R, et al. Guide to using psychotropic medication for the management of behaviour problems among adults with intellectual disability: technical document: section 3: systematic reviews. Birmingham: University of Birmingham; 2007. Reports the results of a comprehensive systematic review into research that assessed the effectiveness of psychotropic medication in the management of behaviour problems in adults with intellectual disability. Provides useful summaries of relevant studies. Available www.LD-Medication.bham.ac.uk
5. Gagiano C, Read S, Thorpe L, et al. Short and long-term efficacy and safety of risperidone in adults with disruptive behaviour disorders. Psychopharmacology 2005; 179:629-636.
6. Shea S, Turgay A, Carroll A, et al. Risperidone in the treatment of disruptive behavioralsymptomsin children with autistic and other pervasive developmental disorders. Pediatrics 2004; 114:e634-e641.
7. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviours in children with subaverage intelligence. Am J Psychiatry 2002; 159:1337-1346.
8. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioural problems. New Engl J Med 2002; 347:314-321.
9. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behaviour disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002; 41:1026-1036.
10. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005; 162:1361-1369.
11. Turgay A, Binder C, Snyder R, Fisman S. Long-term safety and efficacy of risperidone for the treatment of disruptive behaviour disorders in children with subaverage IQs. Pediatrics 2002; 110:34-45.
12. Findling RL, Aman MG, Eerdekens M, et al. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am J Psychiatry 2004; 161:677-684.
13. La Malfa G, Bertelli M, Lassi S. Efficacy and tolerability of quetiapine in patients with mental retardation and behaviour disorders. Nuova Riv Neurol 2003; 13:122-125.
14. Thalayasingam S, Alexander RT, Singh I. The use of clozapine in adults with intellectual disability. J Intellect Disabil Res 2004; 48:572-579.
15. Janowsky DS, Barnhill L, Davis JM. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial. J Clin Psychiatry 2003; 64:1258-1265.
16. Brylewski J, Duggan L. Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database Syst Rev 2004; (3):CD000377.
17. Singh AN, Matson JL, Cooper CL, et al. The use of risperidone among individuals with mental retardation: clinically supported or not? Res Dev Disabil 2005; 26:203-218.
18. Deb S, Sohanpal S, Soni S, et al. The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. J Intellect Disabil Res 2007. www.blackwell-synergy. com/doi/JIR, DOI: 10.1111/j.1365-2788.2007.00950.x.
19. Janowsky DS, Shetty M, Barnhill J, et al. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/ disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial. Int J Neuropsychopharmacol 2005; 8:37-48.
20. Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 1998; 102:427-437.
21. Branford D, Bhaumik S, Naik B. Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 1998; 42:301-306.
22. Lewis MH, Bodfish JW, Powell SB, Golden RN. Clomipramine treatment for stereotype and related repetitive movement disorders associated with mental retardation. Am J Ment Retard 1995; 100:299-312.
23. Troisi A, Vicario E, Nuccetelli F, et al. Effects of fluoxetine on aggressive behavior of adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry 1995; 28:73-76.
24. Bodfish JW, Madison JT. Diagnosis and fluoxetine treatment of compulsive behavior disorder of adults with mental retardation. Am J Ment Retard 1993; 98:360-367.
25. Cook EH Jr, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992; 31:739-745.
26. Markowitz PI. Effect of fluoxetine on self-injurious behavior in the developmentally disabled: A preliminary study. J Clin Psychopharmacol 1992; 12:27-31.
27. La Malfa GP, Bertelli M, Ricca V, et al. Fluvoxamine and mental retardation: Clinical use. Ital J Intellect Impairment 1997; 10:3-6.
28. Sohanpal S, Deb S, Thomas C, et al. The effectiveness of antidepressant medication in the management of behaviour problems in adults with intellectual disabilities: a systematic review. J Intellect Disabil Res 2007. www.blackwell-synergy.com/doi/JIR, DOI: 10.1111/j.1365-2788.2006.00935.x.
29. Janowsky DS, Kraus JE, Barnhill J, et al. Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviours in the intellectually disabled: An open-label retrospective study. J Clin Psychopharmacol 2003; 23:500-504.
30. Verhoeven WMA, Tuinier S. Cyclothymia or unstable mood disorder? A systematic treatment evaluation with valproic acid. J Appl Res Intellect Disabil 2001; 14:147-154.
31. Deb S, Chaplin R, Sohanpal S, et al. The effectiveness of mood stabilisers and antiepileptic medication for the management of behaviour problems in adults with intellectual disabilities: A systematic review. J Intellect Disabil Res 2007. www.blackwell-synergy.com/doi/JIR, DOI: 10.1111/j.1365-2788.2007.00965.x.
32. Willemsen-Swinkels SHN, Buitelaar JK, Nijhof GJ, Van Engeland H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: Double-blind placebo-controlled studies. Arch Gen Psychiatry 1995; 52:766-773.
33. Symons FJ, Thompson A, Rodriguez MC. Self-injurious behavior and the efficacy of naltrexone: a quantitative synthesis. Ment Retard Dev Disabil Res Rev 2004; 10:193-200.
34. King BH, Davanzo P. Buspirone treatment of aggression and self-injury in autistic and nonautistic persons with severe mental retardation. Dev Brain Dysfunction 1996; 90:22-31.
35. Jou R, Handen B, Harden A. Psychostimulant treatment of adults with mental retardation and attention-deficit hyperactivity disorder. Australas Psychiatry 2004; 12:376-379.
36. Kushner SA, Guze BH. Treatment of psychomotor agitation and self-injurious behaviour with estrogen and progesterone treatment in a patient with Sanfilippo syndrome. Gen Hosp Psychiatry 2005; 27:298-300.
37. Lofts RH, Schroeder SR, Maier RH. Effects of serum zinc supplementation on pica behaviour of persons with mental retardation. Am J Ment Retard 1990; 95:103-109.
38. Scotti JR, Evans IM, Mayer LH, Walker P. A meta analysis of intervention research with problem behaviour: treatment validity and standards of practice. Am J Ment Retard 1991; 96:233-256.
39. Didden R, Duker PC, Korzilius H. Meta-analytic study on treatment effectiveness for problem behaviors with individuals who have mental retardation. Am J Ment Retard 1997; 101:387-399.
40. Carr EG, Horner RH, Turnbull AP. Positive behaviour support for people with developmental disabilities: a research synthesis. Washington, DC: American Association on Mental Retardation; 1999.
41. Corrigan PW. Social skills training in adults with psychiatric populations: a meta analysis. J Behav Ther Exp Psychiatry 1991; 22:203-210.